In a laboratory in Tartu, Estonia, researchers have just completed the largest genetic-metabolic study ever conducted—a landmark achievement that rewrites what we know about how our genes shape the way our bodies process food, regulate blood sugar, and manage cholesterol. By combining data from 619,372 people across the Estonian Biobank and the UK Biobank, University of Tartu scientists have created an unprecedented map of the human metabolic system, identifying 88,604 associations between genetic variants and the metabolic markers flowing through our blood.
This matters because metabolic markers—amino acids, cholesterol levels, blood glucose—are powerful windows into our health. Unlike genetic data alone, which can only tell you what mutations you carry, metabolic measurements reveal something far more immediate: how your body is actually working right now, reflecting both your genes and your daily choices. "Metabolic markers found in blood are very useful for creating personalized risk scores because they reflect a person's health status and lifestyle choices. This is information that genetic data alone cannot reveal," explained Priit Palta, Professor of Translational Genomics at the University of Tartu.
The study, published in Nature, examined 249 circulating metabolites—far more than any standard blood test. As Junior Research Fellow Ralf Tambets noted, "While a standard blood test provides information on a handful of markers, we examined metabolism much more broadly and in far greater detail." The sheer scale of this analysis is what made it possible to detect rare genetic variants that only appear when you're looking at hundreds of thousands of people. It's the difference between seeing the outlines of a landscape and having a detailed topographic map.
But size alone doesn't guarantee truth. The research team, including bioinformaticians from the University of Tartu's Institute of Computer Science, had to apply sophisticated statistical methods to sort through what they found. Among the discoveries: the long-suspected link between elevated amino acids and type 2 diabetes isn't actually causal. This is a genuinely important finding. It means that simply lowering these amino acids with medication wouldn't prevent diabetes, even though the correlation is real. Untangling such relationships requires both vast data and deep biological understanding, as Associate Professor Kaur Alasoo emphasized: "Large datasets alone are not enough to uncover causal relationships—you also need a very good understanding of biological mechanisms."
What the research reveals is that metabolism operates as a tightly woven system, not isolated switches. One genetic change rarely flips a single metabolite; instead, genes influence metabolism through interconnected pathways and indirect mechanisms. Understanding this complexity is the gateway to future medicine. The dataset now gives researchers a foundation for identifying which factors truly cause disease and which ones might be druggable targets worth pursuing.
The implications stretch beyond any single discovery. This work demonstrates how combining two major biobanks—one European, one British—can unlock insights neither alone could reveal. And it shows how powerful computing and precise statistics have become tools just as essential as the biology itself. As Palta noted, the new metabolite data in the Estonian Biobank will enable researchers to use existing genetic and health information far more effectively and broadly. For people carrying genetic variants that influence metabolism, this study opens a door to more precise, personalized understanding of their health risks and the real levers that might be pulled to prevent disease.